Over the past 30 years, cord blood and cord tissue have gained popularity and commercial traction due to the valuable stem cells they contain. According to ClinicalTrials.gov, there are over 1,360 clinical trials evaluating the use of cord blood and tissue-derived cells. These studies typically leverage unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Americord® Releases Exosomes Banking with CryoMaxx™ Processing
Americord Registry announces the addition of exosome banking to their suite services, becoming the first company in the United States to do so.
NEW YORK, NEW YORK, US, October 11, 2022 – Americord Registry®, a leader in the cord blood industry, announced the addition of exosome banking to their suite of family-focused services, becoming the first private biobanking company in the United States to do so. Exosomes are tiny, extracellular vesicles that initiate cell-to-cell communication by shuttling cellular components to other cells. Pre-clinical research has shown that exosomes may regulate immune responses, wound healing, and cell growth and development. [Read more…]
Cord Blood Banking in India, a Country That is Home to 1.8 Billion
ReeLabs is an important cord blood banking brand within India. Cord blood banking in this region is of historic importance, because India has an astounding population of 1.4 billion. Representing 18% of the global population, nearly one-in-five people lives in India, placing it head-to-head with China as the world’s most populous country. India’s population growth is fueled by a birth rate (19 births/1,000 population) that substantially exceeds its death rate (7.3 deaths/1,000 population).
If you’re involved with cord blood banking, then you need to pay attention to this enormous consumer market.
In this interview with Dr. Abhijit Bopardikar, Director of ReeLabs, he explains the rise of cord blood banking within India and discusses the importance of pairing stem cell therapy and research applications with stem cell storage services.
[Read more…]
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
August 29, 2022, BALDWIN PARK, CA, — Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years. StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair. [Read more…]
PeptiGrowth Inc. is Launching A Novel Synthetic Peptide BMP4,7 inhibitor (Noggin-like peptide)
July 26, 2022, Tokyo, Japan – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide “BMP4,7 inhibitor (Noggin-like peptide)” which binds to several Bone Morphogenetic Proteins (BMPs) to inhibit its activity like Noggin. It will be marketing this product from July, 2022. [Read more…]
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 62
- Next Page »